Browsing by Subject "angiotensin receptor antagonist"

Now showing items 1-4 of 4

    • Article  

      Alport syndrome from bench to bedside: The potential of current treatment beyond RAAS blockade and the horizon of future therapies 

      Gross, O.; Perin, L.; Constantinou-Deltas, Constantinos D. (2014)
      The hereditary type IV collagen disease Alport syndrome (AS) always leads to end-stage renal failure. Yesterday, for the past 90 years, this course was described as 'inevitable'. Today, RAAS blockade has changed the ...
    • Article  

      Familial C3 Glomerulopathy Associated with CFHR5 Mutations: Clinical Characteristics of 91 Patients in 16 Pedigrees 

      Athanasiou, Yiannis; Voskarides, Konstantinos; Gale, D. P.; Damianou, Loukas; Patsias, Charalambos; Zavros, Michalis; Maxwell, P. H.; Cook, H. T.; Demosthenous, Panayiota; Hadjisavvas, Andreas; Kyriacou, Kyriacos C.; Zouvani, Ioanna; Pierides, Alkis M.; Constantinou-Deltas, Constantinos D. (2011)
      Background and objectives Complement factor H and related proteins (CFHR) are key regulators of the alternative complement pathway, where loss of function mutations lead to a glomerulopathy with isolated mesangial C3 ...
    • Article  

      RAAS inhibition and the course of Alport syndrome 

      Savva, Isavella; Pierides, Alkis M.; Constantinou-Deltas, Constantinos D. (2016)
      Alport syndrome (AS) is a hereditary progressive glomerulonephritis with a high life-time risk for end-stage renal disease (ESRD). Most patients will reach ESRD before the age of 30 years, while a subset of them with milder ...
    • Article  

      The role of mechanical forces in tumor growth and therapy 

      Jain, R. K.; Martin, J. D.; Stylianopoulos, T. (2014)
      Tumors generate physical forces during growth and progression. These physical forces are able to compress blood and lymphatic vessels, reducing perfusion rates and creating hypoxia. When exerted directly on cancer cells, ...